TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  Benzinga

Novartis Projects Faster Growth Through 2030 After Raising Drug Forecasts

Benzinga Logo Benzinga By Vandana Singh
Novartis Projects Faster Growth Through 2030 After Raising Drug Forecasts

Novartis anticipates 5-6% annual sales growth from 2025-2030, raised peak sales projections for key drugs like Kisqali and Scemblix, and expects to maintain operating margins above 40% while planning significant U.S. infrastructure expansion.

Insights
OXY.WS   neutral

Mentioned as a pending acquisition target with no strong positive or negative commentary


NVS   positive

Company raised sales growth projections, increased peak sales estimates for multiple drugs, achieved margin targets ahead of schedule, and planning significant infrastructure investment